Tag: Minimal residual disease

Recent clinical data reveals that long-term survival rates for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults can now reach between 75% and 80%, a profound increase from the historical prognosis. The modern answer to 'what is the survival rate for Ph+ ALL adults?' is highly positive, reflecting the revolutionary impact of targeted therapies on this previously aggressive disease.

Significant advancements in the treatment of Acute Lymphoblastic Leukemia (ALL) have vastly improved outcomes over the past few decades, with survival rates rising dramatically. Key to these improvements is a deeper understanding of **what is the best prognostic factor for ALL** and how it influences therapeutic decisions.